scPharmaceuticals (NASDAQ:SCPH) Coverage Initiated by Analysts at Craig Hallum

Analysts at Craig Hallum assumed coverage on shares of scPharmaceuticals (NASDAQ:SCPH) in a research note issued to investors on Thursday, FlyOnTheWall reports. The firm set a “buy” rating on the stock.

Several other equities research analysts also recently weighed in on SCPH. Maxim Group raised their price target on shares of scPharmaceuticals from $13.00 to $20.00 in a research report on Thursday, May 11th. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of scPharmaceuticals in a research note on Friday, August 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $19.17.

scPharmaceuticals Trading Down 2.4 %

scPharmaceuticals stock opened at $7.00 on Thursday. scPharmaceuticals has a 12 month low of $3.68 and a 12 month high of $12.75. The company has a market capitalization of $251.02 million, a price-to-earnings ratio of -5.26 and a beta of 0.18. The business’s fifty day simple moving average is $8.23 and its two-hundred day simple moving average is $9.12. The company has a current ratio of 17.12, a quick ratio of 16.24 and a debt-to-equity ratio of 0.60.

scPharmaceuticals (NASDAQ:SCPH) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.01. The company had revenue of $1.64 million during the quarter, compared to analysts’ expectations of $1.55 million. As a group, equities analysts predict that scPharmaceuticals will post -1.4 earnings per share for the current fiscal year.

Institutional Trading of scPharmaceuticals

Large investors have recently modified their holdings of the company. Worth Venture Partners LLC increased its position in shares of scPharmaceuticals by 0.3% during the 2nd quarter. Worth Venture Partners LLC now owns 512,337 shares of the company’s stock valued at $5,221,000 after purchasing an additional 1,689 shares during the last quarter. Bank of New York Mellon Corp grew its position in scPharmaceuticals by 5.8% during the first quarter. Bank of New York Mellon Corp now owns 36,185 shares of the company’s stock valued at $328,000 after buying an additional 1,979 shares during the period. State Street Corp increased its holdings in scPharmaceuticals by 15.0% during the second quarter. State Street Corp now owns 17,360 shares of the company’s stock valued at $84,000 after buying an additional 2,260 shares during the last quarter. Boothbay Fund Management LLC raised its position in scPharmaceuticals by 17.6% in the first quarter. Boothbay Fund Management LLC now owns 16,403 shares of the company’s stock worth $149,000 after acquiring an additional 2,450 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in scPharmaceuticals by 17.5% in the first quarter. Tower Research Capital LLC TRC now owns 16,982 shares of the company’s stock worth $154,000 after acquiring an additional 2,533 shares during the period. Institutional investors own 79.60% of the company’s stock.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure.